# Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma

> **NCT05128201** · PHASE2 · RECRUITING · sponsor: **Jiangxi Provincial Cancer Hospital** · enrollment: 63 (estimated)

## Conditions studied

- Oligometastatic Disease

## Interventions

- **RADIATION:** consolidative radiotherapy

## Key facts

- **NCT ID:** NCT05128201
- **Lead sponsor:** Jiangxi Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2025-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05128201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05128201, "Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05128201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*